C4A and thrombophilia: Prevention of terminal complement formation by using a monoclonal antibody against C5 inhibited thrombophilia induced by antiphospholipid antibodies.9 Complement activation and consumption was also confirmed in our patient by the finding that serum levels of C3 and C4 were significantly lowered while disease was highly active.